



Figure 6S.

(A-B) Overall survival (A) and progression-free survival (B) of non-squamous patients with baseline cfDNA tumor fraction ≥ 10% versus < 10%. (C-D) Overall survival (C) and progression-free survival (D) of squamous patients with baseline total cfDNA concentration ≥ median (11.8 ng/ml of plasma) versus < median. E, Association between tumor fraction in baseline cfDNA and clinical characteristics of squamous patients. Arm A, chemotherapy plus pictilicib; Arm B, chemotherapy plus placebo.